XML 75 R59.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Equity-based compensation (Tables)
 12 Months Ended
Dec. 31, 2019
Share-Based Payment Arrangements [Abstract]  
Disclosure of number and weighted average exercise prices of other equity instruments
The below table summarizes unvested share movements for all Alcon equity-based incentive plans from the Spin-off through December 31, 2019:
 
2019
 
Number of
shares in
thousand

 
Weighted average
fair value at grant date in $

 
Fair value in
$ thousand

Replacement awards issued at Spin-off(1)
4,222

 
n/a

 
212,367

Granted
 
 
 
 
 
Restricted awards
625

 
56.1

 
35,037

Performance awards
117

 
58.0

 
6,782

Vested(1)
(108
)
 
n/a

 
(5,432
)
Forfeited(1)
(114
)
 
n/a

 
(5,734
)
Unvested shares at December 31
4,742

 
51.2

 
243,020

(1)
Based on estimated fair value per share at the time of Spin-off.
The below table summarizes unvested share movements for all plans under the Former Parent for the year ended December 31, 2018 (Novartis AG RSAs, RSUs, and PSUs):
 
2018
 
Number of
shares in thousand

 
Weighted average fair value at grant
date in $

 
Fair value in
$ thousand

Unvested shares at January 1
2,800

 
74.4

 
208,300

Granted
 
 
 
 
 
Annual incentive
168

 
83.7

 
14,062

Share savings plans
109

 
85.5

 
9,320

Select North America
689

 
77.9

 
53,673

Select outside North America
141

 
79.8

 
11,252

Long-Term Performance Plan
316

 
88.4

 
27,934

Long-Term Relative Performance Plan
37

 
51.2

 
1,894

Other share awards
205

 
83.1

 
17,036

Vested
(814
)
 
93.0

 
(75,702
)
Forfeited
(208
)
 
80.4

 
(16,723
)
Unvested shares at December 31
3,443

 
72.9

 
251,046
Summary of shares authorized
The table below discloses the number of shares authorized under the plans as of December 31, 2019:
(thousands)
2019

Long-term Incentive Plan
20,000

Deferred Bonus Stock Plan
1,500

Swiss Employee Share Ownership Plan
475

Other share savings plans
275

Authorized as of December 31, 2019
22,250
Disclosure of number and weighted average exercise prices of share options
The following table shows the activity associated with the Novartis AG share options during the year ended December 31, 2018. The weighted average prices in the table below are translated from Swiss francs into USD at historical rates.
 
2018
 
Options
(millions)

 
Weighted average
exercise price
($)

 
Weighted average
intrinsic value
($)

Options outstanding at January 1
0.5

 
61.1

 
24.7

Sold or exercised
(0.1
)
 
59.7

 
29.1

Outstanding at December 31
0.4

 
61.4

 
26.5

Exercisable at December 31
0.4

 
61.4

 
26.5

All Novartis AG share options were granted at an exercise price that was equal to the closing market price of the Novartis AG shares at the grant date. The weighted average Novartis AG share price at the dates of sale or exercise was $86.2.
The following table summarizes information about Novartis AG share options outstanding at December 31, 2018:
 
Options outstanding
Range of exercise prices($)
Number
outstanding (thousand)

 
Average remaining
contractual life (years)
 
Weighted average
exercise price ($)

45 - 55
32

 
0.7
 
52.4

56 - 66
394

 
3.5
 
62.1

Total
426

 
3.3
 
61.4

Options under Novartis equity plan "Select" for North America
The following table shows the activity associated with the Novartis AG American Depositary Receipts ("ADR") options during the period:
 
2018
 
ADR
 options
(millions)

 
Weighted average
exercise price
($)

 
Weighted average
intrinsic value
($)

Options outstanding at January 1
1.8

 
62.5

 
21.4

Sold or exercised
(0.5
)
 
62.4

 
25.8

Outstanding at December 31
1.3

 
62.6

 
23.2

Excercisable at December 31
1.3

 
62.6

 
23.2

All ADR options were granted at an exercise price that was equal to the closing market price of the ADRs at the grant date. The weighted average ADR price at the dates of sale or exercise was $81.4.
The following table summarizes information about ADR options outstanding at December 31, 2018:
 
ADR options outstanding
Range of exercise prices ($)
Number
outstanding
(thousand)

 
Average remaining
contractual life (years)
 
Weighted average
exercise price
($)

45 - 55
30

 
0.6
 
50.7

56 - 66
1,258

 
3.6
 
62.9

Total
1,288

 
3.5
 
62.6